H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32

H.C. Wainwright analyst Joseph Pantginis maintains $Iovance Biotherapeutics(IOVA.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rat

Futu NewsJun 28 23:31 · Ratings

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow JonesJun 28 23:08

Is It Too Late to Buy Iovance Biotherapeutics Stock?

Yahoo FinanceJun 28 16:05

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Iovance BiotherapeuticsJun 28 12:00

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Iovance BiotherapeuticsJun 21 12:00

Iovance Biotherapeutics Is Maintained at Market Outperform by JMP Securities

Dow JonesJun 20 19:54